Earnings ·
Perspective Therapeutics, Inc. reported financial results for the quarter ended June 30, 2026, posting a net loss of…
CATXPerspective Therapeutics, Inc.
Perspective Therapeutics, Inc. reported financial results for the quarter ended June 30, 2026, posting a net loss of $26.8 million, or $0.22 per share, compared to a net loss of $21.5 million in the prior year period. Research and development expenses increased to $21.5 million from $16.6 million, while general and administrative expenses remained stable at $7.8 million. The company held approximately $237 million in cash, cash equivalents, and short-term investments as of June 30, 2026, which management believes is sufficient to fund operations into late 2027. Clinically, the company advanced its VMT-α-NET program toward a Phase 3 study in neuroendocrine tumors, with site activation targeted for year-end 2026 subject to regulatory feedback. Perspective Therapeutics operates as a radiopharmaceutical development company pioneering alpha-emitting treatments for cancers.